Influence of picumast dihydrochloride on the ex vivo histamine release from leucocytes of allergic asthmatic patients.

Abstract

In a pilot study 8 patients with allergic obstructive airway disease were treated with the new compound picumast dihydrochloride (3,4-dimethyl-7-[4-(4-chlorobenzyl)piperazine-1-yl]propoxycoumarine++ + dihydrochloride) 2 x 2 mg daily orally during a period of 8 days additionally to a usual therapy of bronchodilators and corticoids in a steady state. It was demonstrated that the compound inhibited the allergen induced histamine liberation of patients basophils significantly. Compared with a collective of patients without an additional picumast dihydrochloride treatment the effect of the substance was shown more clearly. From reasons of these experimental data picumast dihydrochloride may be of a considerable value as a prophylactic agent in allergic bronchial asthma when given orally.

• Authors: I Zimmermann, A Roesch, W T Ulmer
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 39 Issue 10A Pg. 1351-3 (Oct 1989) ISSN: 0004-4172 [Print] Germany
• PMID: 2483313 (Publication Type: Journal Article)

Chemical References

• Coumarins
• Histamine H1 Antagonists
• picumast

Topics

• Asthma (metabolism)
• Chromatography, High Pressure Liquid
• Coumarins (pharmacology)
• Female
• Histamine H1 Antagonists (pharmacology)
• Histamine Release (drug effects)
• Humans
• Hypersensitivity (metabolism)
• Leukocytes (drug effects, metabolism)
• Male
• Middle Aged